Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IVTA adjunctive to verteporfin photodynamic therapy for predominantly classic CNV in AMD
2005-005290-30Phase 4Completed
- Sponsor
- Semmelweis University Department of Ophthalmology
- Start
- Jun 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of triamcinolone in age-related macular degeneration (AMD) and Subretinal neovascularization, sponsored by Semmelweis University Department of Ophthalmology. Primary endpoint: Ratio of patients losing less than 15 letters of visual acuity. Started Jun 2006; status: completed.
02
Drugs
triamcinolone
03
Conditions
age-related macular degeneration (AMD)Subretinal neovascularization
Beyond the preview
Go deeper on 2005-005290-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005290-30.